John Budd
Rheumatology · Saint Louis, MONPI 1669425989
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 1,104 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations.
Across 1,104 payments — averaging $14.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Amgen$2K
- Johnson & Johnson$2K
- Pfizer$2K
- UCB, Inc.$1K
- Novartis$1K
- plus $5K from 27 others
Across 188 payments — averaging $2072.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$123K
- AbbVie$99K
- Sun Pharmaceutical Industries Inc.$68K
- Gilead$65K
- GSK$21K
- EMD Serono, Inc.$6K
- plus $8K from 3 others
What the payments were for
- Food & beverage$16,45399%
- Education$911%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 150 | $2,371 |
| Amgen(2 entities) | 152 | $2,370 |
| Johnson & Johnson(2 entities) | 177 | $2,212 |
| Pfizer | 155 | $1,893 |
| UCB, Inc. | 80 | $1,238 |
| Novartis | 78 | $1,112 |
| E.r. Squibb & Sons, L.L.C. | 72 | $1,083 |
| GSK | 65 | $1,061 |
| AstraZeneca(2 entities) | 36 | $768 |
| Genentech USA, Inc. | 25 | $514 |
| Lilly USA, LLC | 32 | $514 |
| Sanofi | 8 | $219 |
| Aurinia Pharma U.S., Inc. | 11 | $194 |
| Bristol Myers Squibb | 19 | $154 |
| Janssen Scientific Affairs, LLC | 1 | $119 |
| Radius Health, Inc. | 5 | $110 |
| Boehringer Ingelheim | 5 | $97 |
| Pacira Therapeutics, Inc. | 5 | $75 |
| Organon | 3 | $68 |
| Medexus Pharma, Inc. | 4 | $54 |
| Antares Pharma, Inc. | 3 | $48 |
| Novo Nordisk | 3 | $43 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $38 |
| Fresenius Kabi USA, LLC | 2 | $30 |
| Sandoz | 2 | $28 |
| Merck | 2 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $21 |
| Grifols USA, LLC | 1 | $21 |
| Biogen | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Sobi, Inc | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Cimzia$123
- Tremfya$119
- KRYSTEXXA$117
- SAPHNELO$107
- ANORO ELLIPTA$101
How this compares
$16,544 in reported general payments places this provider in the 85th percentile of 134 rheumatology providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydroxychloroquine Sulfate | 18 | $916 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 14 | $334 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Saint Louis
- Adam KilianSaint Louis$565K
- Alfred KimSaint Louis$486K
- Sona KamatSaint Louis$268K
- Richard BrasingtonSaint Louis$100K
- Akgun InceSaint Louis$45K
- Joseph StauberSaint Louis$37K
- Alissa ChandlerSaint Louis$37K
- Chad RonholmSaint Louis$27K
- Sandra HoffmannSaint Louis$23K
- Michael PaleySaint Louis$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.